The

Evidence MedTEAM

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Mental Health Services

www.samhsa.gov

The MedTEAM Evidence

U.S. Department of Health and Human Services

Substance Abuse and Mental Health Services Administration

Center for Mental Health Services
Acknowledgments

This document was prepared for the Substance Abuse and Mental Health Services Administration 

(SAMHSA) by the New Hampshire-Dartmouth Psychiatric Research Center under contract 

number 280-00-8049 and Westat under contract number 270-03-6005, with SAMHSA, U.S. 

Department of Health and Human Services (HHS). Pamela Fischer, Ph.D., and Crystal Blyler, 

Ph.D., served as SAMHSA Government Project Officers.

Disclaimer

The views, opinions, and content of this publication are those of the authors and contributors 

and do not necessarily reflect the views, opinions, or policies of the Center for Mental Health 

Services (CMHS), SAMHSA, or HHS.

Public Domain Notice

All material appearing in this document is in the public domain and may be reproduced 

or copied without permission from SAMHSA. Citation of the source is appreciated. However, 

this publication may not be reproduced or distributed for a fee without the specific, written 

authorization from the Office of Communications, SAMHSA, HHS.

Electronic Access and Copies of Publication

This publication may be downloaded or ordered at http://www.samhsa.gov/shin. Or, please call 

SAMHSA’s Health Information Network at 1-877-SAMHSA-7 (1-877-726-4727) (English 

and Español).

Recommended Citation

Substance Abuse and Mental Health Services Administration. MedTEAM: The Evidence. HHS Pub. 

No. SMA-10-4548, Rockville, MD: Center for Mental Health Services, Substance Abuse and Mental 

Health Services Administration, U.S. Department of Health and Human Services, 2010.

Originating Office

Center for Mental Health Services

Substance Abuse and Mental Health Services Administration

1 Choke Cherry Road

Rockville, MD 20857

HHS Publication No. SMA-10-4548

Printed 2010
MedTEAM

The Evidence

The Evidence introduces all stakeholders to the research 

literature and other resources on Medication Treatment, 

Evaluation, and Management (MedTEAM). This booklet 

includes the following resources:

 A selected bibliography for further reading;

 References for the citations presented throughout the KIT; 

and

 Acknowledgements of KIT developers and contributors.

For references, see the booklet, The Evidence.
This KIT is part of a series of Evidence-Based Practices KITs created 

by the Center for Mental Health Services, Substance Abuse and 

Mental Health Services Administration, U.S. Department of Health 

and Human Services.

This booklet is part of the MedTEAM KIT that includes a DVD, 

CD-ROM, and seven booklets:

How to Use the Evidence-Based Practices KITs

Getting Started with Evidence-Based Practices

Building Your Program

Training Frontline Staff

Evaluating Your Program

The Evidence

Using Multimedia to Introduce Your EBP
MedTEAM

What’s in The Evidence

Selected Bibliography......................................................... 1

References....................................................................... 19

Acknowledgments ............................................................ 23

The Evidence 1 Selected Bibliography

The Evidence

Selected Bibliography

Antipsychotic 

polypharmacy

Ananth, J., Parameswaran, S., & 

Gunatilake, S. (2004). Antipsychotic 

polypharmacy. Current Pharmaceutical 

Design, 10, 2231-2238.

Canales, P. L., Olsen, J., Miller, A. L., 

& Crismon, M. L. (1999). Role of 

antipsychotic polypharmacotherapy 

in the treatment of schizophrenia. 

CNS Drugs, 12, 179-188.

Ito, H., Koyama, A., & Higuchi, T. 

(2005). Polypharmacy and excessive 

dosing: Psychiatrists’ perceptions of 

antipsychotic drug prescription. British 

Journal of Psychiatry, 187, 243-247.

Stahl, S. M. (1999). Antipsychotic 

polypharmacy, Part 1: Therapeutic 

option or dirty little secret? Journal 

of Clinical Psychiatry, 60, 425-426.

Suzuki, T., Uchida, H., Watanabe, K., 

Yagi, G., & Kashima, H. (2004). 

A clinical case series of switching 

from antipsychotic polypharmacy 

to monotherapy with a secondgeneration agent on patients with 

chronic schizophrenia. Progress 

in Neuro-Psychopharmacology & 

Biological Psychiatry, 28, 361-369.
Selected Bibliography 2 The Evidence

Electronic medical records (EMR)

Major, L. F., & Turner, M. G. (2003). Assessing 

the information management requirements 

for behavioral health providers. Journal 

of Healthcare Management, 48, 323-333; 

discussion, 48, 334-335.

Web sites

http://psychiatry.mc.duke.edu

The Clinical Research Information System 

(CRIS) was developed over the past decade 

by the Duke University School of Medicine 

Department of Psychiatry and Behavioral 

Sciences. Not only a true EMR, but also has 

extensive research and clinical trial capabilities 

that are being used by top centers in the country 

and overseas.

http://www.askesis.com

A link to the vendor for the PsychConsult 

product, developed within and used by 

Western Psychiatric Institute, among others.

http://www.capterra.com/mental-health-software

An extensive list of EMR and other electronic 

(scheduling, notes, prescriptions) software vendors.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retr

ieve&db=PubMed&list_uids=14552101&dopt=Abstract

A link for a 2003 paper that discusses 

assessing behavioral health agency needs 

for EMR implementation.

Fidelity scales 

Bond, G. R., Miller, A. L., Taylor A., Tsai, J., 

Howard, P. B., El-Mallakh, P., et al. (2007). 

A scale to assess fidelity to evidence-based 

principles of medication management for 

schizophrenia. Schizophrenia Bulletin, 33, 469. 

Howard, P. B., El-Mallakh, P., Miller, A. L., 

Rayens, M. K., Bond, G. R., Henderson, K., 

et al. (2009). Prescriber fidelity to a medication 

management evidence-based practice in the 

treatment of schizophrenia. Psychiatric Services, 

60 (7), 929-935.

Taylor, A. C., Bond, G. R., Tsai, J., Howard, P. B., 

El-Mallakh, P., Finnerty, M., et al. (2009). Scales 

to evaluate quality of medication management: 

Development and psychometric properties. 

Administration and Policy in Mental Health 

and Mental Health Services Research. Published 

online February 27, 2009. DOI 10.1007/s10488-

009-0209-z.

Implementing evidence-based 

practices

Drake, R. E., Goldman, H. H., Leff, H. S., 

Lehman, A. F., Dixon, L., Mueser, K. T., et al. 

(2001). Implementing evidence-based practices 

in routine mental health service settings. 

Psychiatric Services, 52, 179-182.

Goldman, H. H., Ganju, V., Drake, R. E., Gorman, 

P., Hogan, M., Hyde, P. S., et al. (2001). Policy 

implications for implementing evidence-based 

practices. Psychiatric Services, 52, 1591-1597.

Sernyak, M. J. (2007). Implementation of 

monitoring and management guidelines 

for second-generation antipsychotics. Journal 

of Clinical Psychiatry, 68(Suppl 4), 14-18.
Torrey, W. C., Drake, R. E., Dixon, L., Burns, B. J., 

Flynn, L., Rush, J., et al. (2001). Implementing 

evidence-based practices for persons with severe 

mental illnesses. Psychiatric Services, 52, 45-50.

Williams, T. L., Cerese, J., Cuny, J., & Sama, D. 

(2008). Outcomes of an initial set of standardized 

performance measures for inpatient mental 

health. Joint Commission Journal on Quality 

and Patient Safety, 34, 399-406.

Medication algorithms 

and guidelines 

American Psychiatric Association Schizophrenia 

Practice Guidelines. (2004). Retrieved from 

http://www.psychiatryonline.org

Canadian Psychiatric Association. (2005, Nov.). 

Clinical Practice Guidelines: Treatment of 

Schizophrenia. Canadian Journal of Psychiatry,

50(13 Suppl 1), 7S-57S.

International Psychopharmacology Algorithm 

Project. (2007). http://www.ipap.org

Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., 

Dickerson, F. B., Dixon, L. B., Goldberg, R., et al. 

(2004). The Schizophrenia Patient Outcomes 

Research Team (PORT): Updated treatment 

recommendations 2003. Schizophrenia Bulletin, 

30, 193-217.

McEvoy, J. P., Scheifler, P. L., & Frances, A., 

(Eds.). (1999). The Expert Consensus Guideline 

Series: Treatment of schizophrenia 1999. Journal 

of Clinical Psychiatry, 60(Suppl 11), 4-80.

Mellman, T. A., Miller, A. L., Weissman, E. M., 

Crismon, M. L., Essock, S. M., & Marder, 

S. R. (2001). Evidence-based pharmacologic 

treatment for people with severe mental illness: 

A focus on guidelines and algorithms. Psychiatric 

Services, 52, 619-625.

Miller, A. L. (2004). PORT Treatment 

Recommendations. Schizophrenia Bulletin, 

30, 601-604.

Moore, T. A., Buchanan, R. W., Buckley, P. F., 

Chiles, J. A., Conley, R. R., Crismon, M. L., et al. 

(2007). The Texas medication algorithm project 

antipsychotic algorithm for schizophrenia: 2006 

update. Journal of Clinical Psychiatry, 68, 

1751-1762.

Texas Department of State Health Services, Texas 

Medication Algorithm Project (TMAP) and 

Texas Implementation of Medication Algorithms 

(TIMA). (2007). Antipsychotic algorithm for the 

treatment of schizophrenia. Available from 

http://www.dshs.state.tx.us/mhprograms/TIMA.shtm

The Evidence 3 Selected Bibliography
Selected Bibliography 4 The Evidence

Medications for schizophrenia 

Baldessarini, R. J., Gardener, D. M., & Garver, 

D. L. (1995). Conversions from clozapine to 

other antipsychotic drugs [Letter to the editor]. 

Archives of General Psychiatry, 52, 1071-1072.

Bell, R., McLaren, A., Gaionos, J., and Copolov, 

D. (1998). The clinical use of plasma clozapine 

levels. Australian and New Zealand Journal of 

Psychiatry, 32, 567-574.

Buckley, P. F. (1999). The role of typical and 

atypical antipsychotic medications in the 

management of agitation and aggression. Journal 

of Clinical Psychiatry, 60(Suppl 10), 52-60.

Buckley, P., Miller, A., Olsen, J., Garver, D., Miller, 

D. D., & Csernansky, J. (2001). When symptoms 

persist: Clozapine augmentation strategies. 

Schizophrenia Bulletin, 27, 615-628.

Carnahan, R. M., Lund, B. C., & Perry, P. J. 

(2001). Ziprasidone, A new atypical antipsychotic 

drug. Pharmacotherapy, 21, 717-730.

Chang, H. H., & Berman, I. (1999). Treatment 

issues for consumers with schizophrenia 

who have obsessive-compulsive symptoms. 

Psychiatric Annals, 29, 529-532.

Conley, R. R., & Mahmoud, R. (2001). A 

randomized double-blind study of risperidone 

and olanzapine in the treatment of schizophrenia 

or schizoaffective disorder. American Journal 

of Psychiatry, 158, 765-774.

Conley, R. R., Tamminga, C.A., Bartko, J. J., 

Richardson, C., Peszke, M., Lingle, J., et al. 

(1998). Olanzapine compared with chlorpromazine 

in treatment-resistant schizophrenia. American 

Journal of Psychiatry, 155, 914-920.

Gilbert, P. L., Harris, M. J., McAdams, L. A., 

& Jeste, D. V. (1995). Neuroleptic withdrawal 

in schizophrenia patients: A review of the 

literature. Archives of General Psychiatry, 

52, 173-188.

Janicak, P. G., Davis, J. M., Preskorn, S. H., 

Ayd, F. J., Jr., Marder, S. R., & Pavuluri, 

M. N. (2006). Principles and Practice 

of Psychopharmacotherapy (4th ed.). 

Baltimore: Lippincott, Williams & Wilkins. 

Jayaram, M. B., Hosalli, P., & Stroup, T. S. (2006). 

Risperidone versus olanzapine for schizophrenia. 

Cochrane Database of Systematic Reviews, (2), 

Art. No.: CD005237. DOI: 10.1002/14651858.

CD005237.pub2.

Kinghorn, W. A., & McEvoy, J. P. (2005). 

Aripiprazole: Pharmacology, efficacy, 

safety and tolerability. Expert Review 

of Neurotherapeutics, 5, 297-307.

Lieberman, J. A., Safferman, A. Z., Pollack, S., 

Szymanski, S., Johns, C., Howard, A., et al. 

(1994). Clinical effects of clozapine in chronic 

schizophrenia: Response to treatment and 

predictors of outcome. American Journal 

of Psychiatry, 151, 1744-1752.

Lindenmayer, J. P., & Khan, A. (2004). 

Pharmacological treatment strategies 

for schizophrenia. Expert Review of 

Neurotherapeutics, 4, 705-723.

Lindenmayer, J. P., Khan, A., Iskander, A., Abad, 

M. T., & Parker, B. (2007). A randomized 

controlled trial of olanzapine versus haloperidol 

in the treatment of primary negative symptoms 

and neurocognitive deficits in schizophrenia. 

Journal of Clinical Psychiatry, 68, 368-379.
The Evidence 5 Selected Bibliography

Luft, B., & Taylor, D. (2006). A review of atypical 

antipsychotic drugs versus conventional 

medication in schizophrenia. Expert Opinion 

on Pharmacotherapy, 7, 1739-1748.

Marder, S. R. (2000). Schizophrenia: Somatic 

treatment. In B. J. Sadock and V. A. Sadock 

(Eds.), Comprehensive textbook of psychiatry 

VII (pp. 1199-1210). Philadelphia: Lippincott, 

Williams & Wilkins: 1199-1210.

Meltzer, H. Y., & Bobo, W. V. (2006). Interpreting 

the efficacy findings in the CATIE study: 

What clinicians should know. CNS Spectrums, 

11(7 Suppl 7), 14-24.

Meyer, J. M. (2007). Antipsychotic safety and 

efficacy concerns. Journal of Clinical Psychiatry, 

68(Suppl 14), 20-26.

Miller, A. L., Dassori, A., Ereshefsky, L., & 

Crismon, M. L. (2001). Recent issues and 

developments in antipsychotic use. In D. L. 

Dunner & J. F. Rosenbaum (Eds.), Psychiatric 

clinics of North America annual of drug 

therapy (pp. 209-235). Philadelphia: W. B. 

Saunders Company.

Miller, A. L., McEvoy, J. P., Jeste, D., & Marder, 

S. (2006). Treatment of chronic schizophrenia. 

In J. A. Lieberman, T. S. Stroup, & D. O. Perkins 

(Eds.), Textbook of schizophrenia (pp. 365-

381). Arlington, VA: American Psychiatric 

Publishing, Inc.

Reznik, I., & Sirota, P. (2000). Obsessive 

and compulsive symptoms in schizophrenia: 

A randomized controlled trial with fluvoxamine 

and neuroleptics. Journal of Clinical 

Psychopharmacology, 20, 410-416.

Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, 

M., Schwartz, B., Dorfman-Etrog, P. et al. 

(1997). Sulpiride augmentation in people with 

schizophrenia partially responsive to clozapine. 

A double-blind, placebo-controlled study. British 

Journal of Psychiatry, 171, 569-573.

Siris, S. G. (2000). Depression in schizophrenia: 

Perspective in the era of “atypical” antipsychotic 

agents. American Journal of Psychiatry, 157, 

1379-1389.

Stroup, T. S., Lieberman, J. A., McEvoy, J. P., 

Swartz, M. S., Davis, S. M., Rosenheck, R. A., 

et al. (2006). Effectiveness of olanzapine, 

quetiapine, risperidone, and ziprasidone in 

patients with chronic schizophrenia following 

discontinuation of a previous atypical 

antipsychotic. American Journal of Psychiatry, 

163, 611-622.

Stroup, T. S., Lieberman, J. A., McEvoy, J. P., 

Swartz, M. S., Davis, S. M., Capuano, G. A., 

et al. (2007). Effectiveness of olanzapine, 

quetiapine, and risperidone in patients with 

chronic schizophrenia after discontinuing 

perphenazine: A CATIE study. American Journal 

of Psychiatry, 164, 415-427.

Tandon, R., Belmaker, R. H., Gattaz, W. F., LopezIbor, Jr., J. J., Okasha, A., Singh, B., et al. (2008). 

World Psychiatric Association Pharmacopsychiatry 

Section statement on comparative effectiveness 

of antipsychotics in the treatment of schizophrenia. 

Schizophrenia Research, 100, 20-38.

Thompson, C. (1994). The use of high-dose 

antipsychotic medication. British Journal of 

Psychiatry, 164, 448-458.

Viguera, A. C., Baldessarini, R. J., Hegarty, J. D., 

van Kammen, D. P., & Tohen, M. (1997). 

Clinical risk following abrupt and gradual 

withdrawal of maintenance neuroleptic 

treatment. Archives of General Psychiatry, 

54, 49-55.

Yen, Y.-C., Lung, F. W., & Chong, M. Y. (2004). 

Adverse effects of risperidone and haloperidol 

treatment in schizophrenia. Progress in NeuroPsychopharmacology & Biological Psychiatry, 

28, 285-290.
Selected Bibliography 6 The Evidence

Medication update Web sites 

and newsletters 

Biological Therapies in Psychiatry.

http://www.btpnews.com

Child & Adolescent Psychiatry Alerts.

http://www.alertpubs.com/child.htm

Current Psychiatry. 

http://www.currentpsychiatry.com

Epocrates. Online–Free drug and clinical 

reference for the web browser. 

http://www.epocrates.com/products/online/index.html

Evidence-Based Answers to Clinical Questions 

for Busy Clinicians (2009). The Centre for 

Clinical Effectiveness, Southern Health, at the 

Monash Institute of Health Services Research, 

Melbourne, Australia. 

http://www.southernhealth.org.au/icms_docs/2145_

EBP_workbook.pdf

Food and Drug Administration: Drugs@FDA. 

http://www.accessdata.fda.gov/scripts/cder/

drugsatfda

Food and Drug Administration: Center for Drug 

Evaluation and Research. 

http://www.fda.gov/cder/drug/default.htm

Indiana University, Division of Clinical 

Pharmacology: Drug Interaction Table 

(Cytochrome P450 System). 

http://medicine.iupui.edu/flockhart

International Bibliographic Information on Dietary 

Supplements (IBIDS). 

http://ods.od.nih.gov/Health_Information/IBIDS.aspx

Journal Watch: Psychiatry. 

http://psychiatry.jwatch.org

MedlinePlus: Medicines. 

http://www.nlm.nih.gov/medlineplus/medicines.html

Psychiatry Drug Alerts.

http://www.alertpubs.com/Psych.htm

Psychiatry Weekly. 

http://www.psychiatryweekly.com 

Psychopharm Review (formerly International Drug 

Therapy Newsletter). 

http://www.lww.com/resources/cmeinfo/

internationaldrugtherapy.html

The Brown University Child and Adolescent 

Psychopharmacology Update. 

http://www.wiley.com/WileyCDA/WileyTitle/

productCd-CPU.html

The Brown University Geriatric 

Psychopharmacology Update. 

http://www.wiley.com/WileyCDA/WileyTitle/

productCd-GPU.html

The Brown University Psychopharmacology Update. 

http://www.wiley.com/WileyCDA/WileyTitle/

productCd-PU.html

The Carlat Psychiatry Report. 

http://www.thecarlatreport.com
The Evidence 7 Selected Bibliography

Quality of medication 

management and 

documentation 

Adams, A. S., Soumerai, S. B., Lomas, J., & RossDegnan, D. (1999). Evidence of self-report 

bias in assessing adherence to guidelines. 

International Journal for Quality in Health 

Care, 11, 187-192.

American Psychiatric Association. (2004). Practice 

guideline for the treatment of patients with 

schizophrenia (2nd ed.). Arlington, VA: Author.

Bollini, P., Pampallona, S., Nieddu, S., Bianco, M., 

Tibaldi, G., & Munizza, C. (2008). Indicators of 

conformance with guidelines of schizophrenia 

treatment in mental health services. Psychiatric 

Services, 59, 782-791.

Cradock, J., Young, A. S., et al. (2001). The accuracy 

of medical record documentation in schizophrenia. 

Journal of Behavioral Health Services and 

Research, 28, 456-465.

Lehman, A. F. (1999). Improving treatment 

for persons with schizophrenia. Psychiatric 

Quarterly, 70, 259-272. 

Lehman, A. F., Steinwachs, D. M., & the CoInvestigators of the PORT Project. (1998). 

Translating research into practice: The 

schizophrenia PORT treatment recommendations. 

Schizophrenia Bulletin, 24, 1-10. 

Marder, S. R., Essock, S. M., Miller, A. L., 

Buchanan, R. W., Davis, J. M., Kane, J. M., 

et al. (2002). The Mount Sinai conference 

on the pharmacotherapy of schizophrenia. 

Schizophrenia Bulletin, 28, 5-16.

Owen, R. R., Thrush, C. R., Hudson, T. J., Mallory, 

S. R., Fischer, E. P., Clardy, J. A., et al. (2002). 

Using an explicit guideline-based criterion and 

implicit review to assess antipsychotic dosing 

performance for schizophrenia. International 

Journal for Quality in Health Care, 14, 199-206.

Rush, A. J., Rago, W. V., Crismon, M. L., Toprac, 

M. G., Shon, S. P., Suppes, T., et al. (1999). 

Medication treatment for the severely and 

persistently mentally ill: The Texas Medication 

Algorithm Project. Journal of Clinical 

Psychiatry, 60, 284-291.

Smith, T. E., & Docherty, J. P. (1998). Standards 

of care and clinical algorithms for treating 

schizophrenia. Psychiatric Clinics of North 

America, 21, 203-220. 

Uttaro, T., Finnerty, M., White, T., Gaylor, R., & 

Shindelman, L. (2007). Reduction of concurrent 

antipsychotic prescribing practices through the 

use of PSYCKES. Administration and Policy 

in Mental Health and Mental Health Services 

Research, 34, 57-61.

Young, A. S., Sullivan, G., Burnam, M. A., & 

Brook, R. H. (1998). Measuring the quality of 

outpatient treatment for schizophrenia. Archives 

of General Psychiatry, 55, 611-617.
Selected Bibliography 8 The Evidence

Racial and ethnic effects 

on medication management 

Frackiewicz, E. J., Sramek, J. J., Herrera, J. M., 

Kurtz, N.., & Cutler, N. R. (1997). Ethnicity 

and antipsychotic response. Annals of 

Pharmacotherapy, 31, 1360-1369.

Leckband, S. G., Bishop, J. R., & Ellingrod, V. L. 

(2007). Pharmacogenomics in psychiatry. Journal 

of Pharmacy Practice, 20, 252-264.

Malhotra, A. K., Murphy, G. M., & Kennedy, J. L. 

(2004). Pharmacogenetics of psychotropic drug 

response. American Journal of Psychiatry, 161, 

780-796.

Ng, C. H., Chong, S. A., Lambert, T., Fan, A., 

Hackett, L. P., & Mahendran, R. (2005). An 

inter-ethnic comparison study of clozapine 

dosage, clinical response, and plasma levels. 

International Clinical Psychopharmacology, 

20, 163-168.

U.S. Department of Health and Human Services. 

(2001). Mental health: Culture, race, and 

ethnicity— A supplement to mental health: 

A report of the Surgeon General. Rockville, 

MD: U.S. Department of Health and Human 

Services, Substance Abuse and Mental Health 

Services Administration, Center for Mental 

Health Services.

Recovery and remission

Allott, P., Loganathan, L., & Fulford, K. W. M. 

(2002). Discovering hope for recovery: A review 

of a selection of recovery literature, implications 

for practice and systems change. Canadian 

Journal of Community Mental Health, 21, 13-33.

American Psychiatric Association (2005). 

Use of the concept of recovery: Position 

statement Arlington, VA: Author. Retrieved from 

http://www.psych.org/Departments/EDU/

Library/APAOfficialDocumentsandRelated/

PositionStatements/200504.aspx 

Andreasen, N. C., Carpenter, W. T., Kane, J. M., 

Lasser, R. A., Marder, S. R., & Weinberger, 

D. R. (2005). Remission in schizophrenia: 

Proposed criteria and rationale for consensus. 

American Journal of Psychiatry, 162, 441–449. 

Anthony, W., Rogers, E. S., & Farkas, M. (2003). 

Research on evidence-based practices: Future 

directions in an era of recovery. Community 

Mental Health Journal, 39, 101-114.

Campbell-Orde, T., Chamberlin, J., Carpenter, 

J., & Leff, H. S. (Eds.). (2005). Measuring the 

promise: A compendium of recovery measures

(Vol. II). (Publication No. 55). Cambridge, MA: 

The Evaluation Center @ Human Services 

Research Institute.

Center for Mental Health Services. (2005). 

National consensus statement on mental health 

recovery (Publication No. SMA-05-4129). 

Rockville, MD: Substance Abuse and 

Mental Health Services Administration, U.S. 

Department of Health and Human Services.
The Evidence 9 Selected Bibliography

Copeland, Mary Ellen. (1997). Wellness Recovery 

Action Plan. West Dummerston, VT: Peach Press.

Davidson, L., Schmutte, T., Dinzeo, T., & AndresHyman, R. (2008). Remission and recovery 

in schizophrenia: Practitioner and patient 

perspectives. Schizophrenia Bulletin, 34:5-8.

Del Vecchio, P., & Blyler, C. R. (2009). Identifying 

critical outcomes and setting priorities for 

mental health services research. In J. Wallcraft, 

B. Schrank, & M. Amering (Eds.), Handbook 

of service user involvement in mental health 

research (pp. 99-112). Hoboken, NJ: 

Wiley-Blackwell.

Dumont, J. M., Ridgway, P., Onken, S. J., Dornan, 

D. H., & Ralph, R. O. (2006). Mental health 

recovery: What helps and what hinders? 

A national research project for the development 

of recovery facilitating system performance 

indicators. Alexandria, VA: National Association 

of State Mental Health Program Directors, 

National Technical Assistance Center for State 

Mental Health Planning.

Evaluation Center @ Human Services Research 

Institute. (2007). Addendum to measuring the 

promise: A compendium of recovery measures, 

Volume II. Cambridge, MA: Author.

Farkas, M., Gagne, C., Anthony, W., & 

Chamberlin, J. (2005). Implementing recovery 

oriented evidence based programs: Identifying 

the critical dimensions. Community Mental 

Health Journal, 41, 141-158.

Jacobson, N. (2004). In recovery: The making of 

mental health policy. Nashville, TN: Vanderbilt 

University Press.

Kane, J. M. (2008). An evidence-based strategy for 

remission in schizophrenia. Journal of Clinical 

Psychiatry, 69(Suppl 3), 25-30.

Ralph, R. O., Kidder, K., & Phillips, D. (2000). 

Can we measure recovery? A compendium 

of recovery and recovery-related instruments

(Publication No. 43). Cambridge, MA: 

The Evaluation Center @Human Services 

Research Institute.

Ralph, Ruth O. (2000). Review of recovery 

literature: A synthesis of a sample of recovery

Literature 2000. Alexandria, VA: National 

Association of State Mental Health Program 

Directors, National Technical Assistance Center 

for State Mental Health Planning.

Ralph, R. O., Lambert, D., & Kidder, K. A. 

(2002). Recovery perspective and evidencebased practice for people with serious mental 

illness: A guideline developed for the Behavioral 

Health Recovery Management Project. An 

Initiative of Fayette Companies, Peoria, IL; 

Chestnut Health Systems, Bloomington, 

IL; and the University of Chicago Center 

for Psychiatric Rehabilitation. Retrieved 

from http://www.bhrm.org/guidelines/Ralph%20

Recovery.pdf

Ridgway, P. (2001). Restorying psychiatric 

disability: Learning from first person recovery 

narratives. Psychiatric Rehabilitation Journal, 

24, 335-344.

Sowers, W. (2005). Transforming systems of 

care: The American Association of Community 

Psychiatrists Guidelines for Recovery Oriented 

Services. Community Mental Health Journal, 41, 

757-774.

Young, S. L., & Ensing, D. S. (1999). Exploring 

recovery from the perspective of people with 

psychiatric disabilities. Psychiatric Rehabilitation

Journal, 22, 219-231.
Selected Bibliography 10 The Evidence

Shared decisionmaking 

and adherence 

Adams, N., & Grieder, D. (2004). Treatment 

planning for person-centered care: The road to 

mental health and addiction recovery. Burlington, 

Massachusetts: Elsevier Academic Press.

Adams, J., & Scott, J. (2000). Predicting 

medication adherence in severe mental 

disorders. Acta Psychiatrica Scandinavica, 

101, 119-124.

Agarwal, M. R., Sharma, V. K., Kishore Kumar, 

K. V, & Lowe, D. (1998). Non-compliance 

with treatment in patients suffering from 

schizophrenia: A study to evaluate possible 

contributing factors. International Journal 

of Social Psychiatry, 44, 92-106.

Byerly, M. J., Nakonezny, P. A., & Rush, A. J. 

(2008). The Brief Adherence Rating Scale 

(BARS) validated against electronic monitoring 

in assessing the antipsychotic medication 

adherence of outpatients with schizophrenia 

and schizoaffective disorder. Schizophrenia 

Research, 100, 60-69.

Charles, C., Gafni, A., & Whelan, T. (1997). Shared 

decision-making in the medical encounter: What 

does it mean? (Or it takes at least two to tango). 

Social Science & Medicine, 44, 681-692.

Corrigan, P. W., Liberman R. P., & Engel, J. D. 

(1990). From noncompliance to collaboration 

in the treatment of schizophrenia. Hospital & 

Community Psychiatry, 41, 1203-1211.

Cramer, J. A., & Rosenheck, R. (1998). 

Compliance with medication regimens for mental 

and physical disorders. Psychiatric Services, 49,

196-201.

Deegan, P. E., Rapp, C., Holter, M., & Riefer, M. 

(2008). Best practices: A program to support 

shared decision making in an outpatient 

psychiatric medication clinic. Psychiatric 

Services, 59, 603-605.

Elwyn, G., Edwards, A., Gwyn, R., & Grol, R. 

(1999). Towards a feasible model for shared 

decision-making: Focus group study with general 

practice registrars. BMJ, 319, 753-756.

Fallon, I. R. H. (1984). Developing and 

maintaining adherence to long-term drug-taking 

regimens. Schizophrenia Bulletin, 10, 412-417.

Frank, A. F., & Gunderson, J. G. (1990). The role 

of the therapeutic alliance in the treatment 

of schizophrenia: Relationship to course and 

outcome. Archives of General Psychiatry, 47, 

228-236.

Frosch, D. L., & Kaplan, R. M. (1999). Shared 

decision-making in clinical medicine: Past 

research and future directions. American Journal 

of Preventive Medicine, 17, 285-294.

Garavan, J., Browne, S. Gervin, M., Lane, 

A., Larkin, C., & O’Callaghan, E. (1998). 

Compliance with neuroleptic medication 

in outpatients with schizophrenia; relationship 

to subjective response to neuroleptics; attitudes 

to medication and insight. Comprehensive 

Psychiatry, 39, 215-219.

Kelly, G. R., & Scott, J. A. (1990). Medication 

compliance and health education among 

outpatients with chronic mental disorders. 

Medical Care, 28, 1181-1197.

Kemp, R., Kirov, G., Everitt, B., Hayward, P., & 

David, A. (1998). Randomised controlled trial of 

compliance therapy–18 month follow-up. British 

Journal of Psychiatry, 172, 413-419.
The Evidence 11 Selected Bibliography

Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, 

S. G., & Jeste, D. V. (2002). Prevalence of and 

risk factors for medication nonadherence in 

patients with schizophrenia: A comprehensive 

review of recent literature. Journal of Clinical 

Psychiatry, 63, 892-909.

Masand, P. S., & Narasimhan, M. (2006). 

Improving adherence to antipsychotic 

pharmacotherapy. Current Clinical 

Pharmacology, 1, 47-56.

Macpherson, R., Jerrom, B., & Hughes, A. (1996). 

A controlled study of education about drug 

treatment in schizophrenia. British Journal 

of Psychiatry, 168, 709-717.

Nosé, M., Barbui, C., & Tansella, M. (2003). 

How often do patients with psychosis fail to 

adhere to treatment programmes? A systematic 

review. Psychological Medicine, 33, 1149-1160. 

Published online 9/27/03. Available from 

http://journals.cambridge.org

Olfson, M., Mechanic, D., Hansell, S., Boyer, 

C. A., Walkup, J., & Weiden, P. J. (2000). 

Predicting medication noncompliance after 

hospital discharge among patients with 

schizophrenia. Psychiatric Services, 51, 216-222.

Perkins, D. O., Johnson, J. L., Hamer, R. M., 

Zipursky, R. B., Keefe, R. S., Centorrhino, 

F., et al. (2006). Predictors of antipsychotic 

medication adherence in patients recovering 

from a first psychotic episode. Schizophrenia 

Research, 83, 53-63.

Ruscher, S. M., de Wit, R., & Mazmanian, D. 

(1997). Psychiatric patients’ attitudes about 

medication and factors affecting noncompliance. 

Psychiatric Services, 48, 82-85.

Stevenson, F. A., Barry, C. A., Britten, N., Barber, 

N., & Bradley, C. P. (2000). Doctor-patient 

communication about drugs: The evidence 

for shared decision-making. Social Science 

& Medicine, 50, 829-840. 

Tay, S. E. (2007). Compliance therapy: An 

intervention to improve inpatients’ attitudes 

toward treatment. Journal of Psychosocial 

Nursing and Mental Health Services, 45, 29-37.

Uzenoff, S. R., Perkins, D. O., Hamer, R. M., 

Wiesen, C. M., & Penn, D. L. (2008). A 

preliminary trial of adherence-coping-education 

(ACE) therapy for early psychosis. Journal of 

Nervous and Mental Disease, 196, 572-575.

Van Putten, T., & May, R. A. (1978). Subjective 

response as a predictor of outcome in 

pharmacotherapy. Archives of General 

Psychiatry, 35, 477-480.

Van Putten, T., May, P. R. A., Marder, S. R., & 

Wittmann, L. A. (1981). Subjective response 

to antipsychotic drugs. Archives of General 

Psychiatry, 38, 187-190.

Velligan, D. I., Diamond, P. M., Mintz, J., Maples, 

N., Li, X., Zeber, J., et al. (2008). The use of 

individually tailored environmental supports 

to improve medication adherence and outcomes 

in schizophrenia. Schizophrenia Bulletin, 34, 

483-493.

Velligan, D. I., Lam, F., Ereshefsky, L., & Miller, 

A. L. (2003). Psychopharmacology: Perspectives 

on medication adherence and atypical 

antipsychotic medications. Psychiatric Services, 

54, 665-667.

Velligan, D., Lam, Y. W. F., Glahn, D. C., Barrett, 

J. A., Maples, N. J., Ereshefsky, L., et al. 

(2006). Defining and assessing adherence to 

oral antipsychotics: A review of the literature. 

Schizophrenia Bulletin, 32, 724-742.

Velligan, D. I., Wang, M., Diamond, P., Glahn, 

D. C., Castillo, D., Bendle, S., et al. (2007). 

Relationships among subjective and objective 

measures of adherence to oral antipsychotic 

medications. Psychiatric Services, 58, 1187-1192.
Selected Bibliography 12 The Evidence

Side effects of antipsychotic 

medication 

American Diabetes Association Clinical Practice 

Recommendations 2009. (2009). Diabetes Care, 

32, S1-97.

American Diabetes Association, American 

Psychiatric Association, American Association 

of Clinical Endocrinologists, & North American 

Association for the Study of Obesity. (2004). 

Consensus development conference on 

antipsychotic drugs and obesity and diabetes. 

Diabetes Care, 27, 596-601.

Birkenaes, A. B., Birkeland, K. I., Engh, J. A., 

Færden, A., Jonsdottir, H., Ringen, P. A., 

et al. (2008). Dyslipidemia independent of 

body mass in antipsychotic-treated patients 

under real-life conditions. Journal of Clinical 

Psychopharmacology, 28, 132-137.

Byerly, M., Suppes, T., Tran, Q. V., & Baker, R. A. 

(2007). Clinical implications of antipsychoticinduced hyperprolactinemia in patients 

with schizophrenia spectrum or bipolar 

spectrum disorders: Recent developments 

and current perspectives. Journal of Clinical 

Psychopharmacology, 27, 639-661.

Drici, M. D., & Priori, S. (2007) Cardiovascular 

risks of atypical antipsychotic drug treatment. 

Pharmacoepidemiology & Drug Safety, 16, 882-

890.

Glassman, A. H., & Bigger, J. T. (2001). 

Antipsychotic drugs: Prolonged QTC interval, 

torsade de pointes, and sudden death. American

Journal of Psychiatry, 158, 1774-1782.

Henderson, D. C., Nguyen, D. D., Copeland, 

P. M., Hayden, D. L., Borba, C. P., Louie, P. M., 

et al. (2005). Clozapine, diabetes mellitus, 

hyperlipidemia, and cardiovascular risks and 

mortality: Results of a 10-year naturalistic study. 

Journal of Clinical Psychiatry, 66, 1116-1121.

Hummer, M., & Huber, J. (2004). 

Hyperprolactinaemia and antipsychotic therapy 

in schizophrenia. Current Medical Research & 

Opinion, 20, 189-197.

Iqbal, M. M., Rahman, A., Husain, Z., Mahmud, 

S. Z., Ryan, W. F., & Feldman, J. M. (2003). 

Clozapine: A clinical review of adverse effects 

and management. Annals of Clinical Psychiatry, 

15, 33-48.

Juvonen, H., Reunanen, A., Haukka, J., Mukonen, 

M. Suvisaari, J., Arajärvi, R., et al. (2007). 

Incidence of schizophrenia in a nationwide 

cohort of patients with type 1 diabetes mellitus. 

Archives of General Psychiatry, 64, 894-899.

Kennedy, A., Tapp, A., Kelly, W. S., Kilzieh, 

N., & Wood, A. E. (2006). Abstinence, 

anticipation, reduction, and treatment (AART): 

A stepwise approach to the management of 

atypical antipsychotic side effects. Essential 

Psychopharmacology, 7, 1-14.

Kleinberg, D. L., Davis, J. M., de Coster, 

R., Van Baelan, B., & Brecher, M. (1999). 

Prolactin levels and adverse effects in patients 

treated with risperidone. Journal of Clinical 

Psychopharmacology, 19, 57-61.

Lamberti, J. S., Costea, G. O., Olson, D., Crilly, 

J. F., Maharaj, K., Tu, X., et al. (2005). Diabetes 

mellitus among outpatients receiving clozapine: 

Prevalence and clinical-demographic correlates. 

Journal of Clinical Psychiatry, 66, 900-906.

Leslie, D. L., & Rosenheck, R. A. (2004). 

Incidence of newly diagnosed diabetes 

attributable to atypical antipsychotic 

medications. American Journal of Psychiatry, 

161, 1709-1711.

Malhotra, S., & McElroy, S. L. (2002). Medical 

management of obesity associated with mental 

disorders. Journal of Clinical Psychiatry, 

63(Suppl 4), 24-32.
The Evidence 13 Selected Bibliography

Melkersson, K. I., Dahl, M. L., & Hulting, 

A. L. (2004). Guidelines for prevention and 

treatment of adverse effects of antipsychotic 

drugs on glucose-insulin homeostasis and lipid 

metabolism. Psychopharmacology, 175, 1-6.

Mortensen, P. B., and Eaton, W. W. (2008). 

Diabetes mellitus and schizophrenia. 

Archives of General Psychiatry, 65, 237-238.

Murashita, M., Inoue, T., Kusumi, I., Nakagawa, 

S., Itoh, K., Tanaka, T., et al. (2007). Glucose 

and lipid metabolism of long-term risperidone 

monotherapy in patients with schizophrenia. 

Psychiatry and Clinical Neurosciences, 61, 

54-58.

Nakajima, M., Terao, T., Iwata, N., & Nakamura, J. 

(2005). Switching female schizophrenic patients 

to quetiapine from conventional antipsychotic 

drugs: Effects on hyperprolactinemia. 

Pharmacopsychiatry, 38, 17-19.

Nasrallah, H. A., Meyer, J. M., Goff, D. C., 

McEvoy, J. P., Davis, S. M, Stroup, T. S., et al. 

(2006). Low rates of treatment for hypertension, 

dyslipidemia and diabetes in schizophrenia: Data 

from the CATIE schizophrenia trial sample at 

baseline. Schizophrenia Research, 86, 15-22.

Newcomer, J. W., Haupt, D. W., Fucetola, R., 

Melson, A. K., Schweiger, J. A., Cooper, B. P., 

et al. (2002). Abnormalities in glucose regulation 

during antipsychotic treatment of schizophrenia. 

Archives of General Psychiatry, 59, 337-345.

Parks J., Svendsen, D., Singer, P., & Foti, M. E. 

(Eds.) (2006). Morbidity and mortality in 

people with serious mental illness. [Thirteenth 

in a series of technical reports.] Alexandria, 

VA: National Association of State Mental 

Health Program Directors (NAS. H.D) 

Medical Directors Council Available from 

http://www.nasmhpd.org

Reinstein, M. J., Sirotovskaya, L. A., Jones, L. E., 

Mohan, S., & Chasanov, M. A. (1999). Effect 

of clozapine-quetiapine combination therapy 

on weight and glycaemic control: Preliminary 

findings. Clinical Drug Investigations, 

18, 99-104.

Shirzadi, A. A., & Ghaemi, S. N. (2006). Side 

effects of atypical antipsychotics: Extrapyramidal 

symptoms and the metabolic syndrome. Harvard 

Review of Psychiatry, 14, 152-164.

Srihari, V. H., Tek, C., Chwastiak, L. A., Woods, 

S. W., & Steiner, J. L. (2007). Best practices: 

Surveillance and management of diabetes in a 

CMHC Population. Psychiatric Services, 58, 

1151-1153.
Selected Bibliography 14 The Evidence

Special topics 

Altshuler, L., Hendrick, V., & Cohen, L. S. (1998). 

Course of mood and anxiety disorders during 

pregnancy and the postpartum period. Journal of 

Clinical Psychiatry, 59(Suppl 2), 29-33.

Altshuler, L. L, Cohen L., Szuba, M. P., Burt, V. K., 

Gitlin, M., & Mintz, J. (1996). Pharmacologic 

management of psychiatric illness during 

pregnancy: Dilemmas and guidelines. American 

Journal of Psychiatry, 153, 592-606.

Altshuler, L. L., Cohen, L. S., Moline, M. L., 

Kahn, D. A., Carpenter, D., & Docherty, J. P. 

(2001). Treatment of depression in women 

(Consensus Guideline Series). Postgraduate 

Medicine (special report), 1-107.

American Academy of Pediatrics, Committee on 

Drugs. (2000). Use of psychoactive medication 

during pregnancy and possible effects on the 

fetus and newborn. Pediatrics, 105, 880-887.

Arango, C., Parellada, M., & Moreno, D. M. 

(2004). Clinical effectiveness of new generation 

antipsychotics in adolescent patients. 

European Neuropsychopharmacology, 14(Suppl 

4), S471-479.

Briggs, G. G., Freeman, R. K., & Yaffe, S. J. 

(2008). Drugs in pregnancy and lactation: 

A reference guide to fetal and neonatal 

risk, (8th ed). Philadelphia: Lippincott, 

Williams & Wilkins.

Briggs Update: Drugs in Pregnancy 

and Lactation. Available from

http://www.briggsdrugsinpregnancy.com 

Bupropion Pregnancy Registry Final Report. (2008). 

A project of Glaxo-SmithKline. Available from 

http://pregnancyregistry.gsk.com/bupropion.html

Byerly, M. J., Weber, M. T., Brooks, D. L., Snow, 

L. R., Worley, M. A., & Lescoufleur, E., et 

al. (2001). Antipsychotic medications and the 

elderly: Effects on cognition and implications 

for use. Drugs & Aging, 18, 45-61.

Centre for Addiction and Mental Health (CAMH). 

(2007). Psychotropic medications and other 

substances during pregnancy and lactation: 

A handbook for health care providers. Toronto, 

Ontario, Canada: Author. Available from 

http://www.camh.net/Publications/Resources_for_

Professionals/Pregnancy_Lactation/index.html

Chambers, C. (1996). Birth outcomes in pregnant 

women taking fluoxetine. New England Journal 

of Medicine, 335, 1010-1015.

Cohen, L. S., & Rosenbaum, J. F. (1998). 

Psychotropic drug use during pregnancy: 

Weighing the risks. Journal of Clinical 

Psychiatry, 59(Suppl 2), 18-28.

Craig, M., & Abel, K. (2001). Prescribing for 

psychiatric disorders in pregnancy and lactation. 

Best Practice & Research Clinical Obstetrics & 

Gynaecology, 15, 1013-1030.

D. V.ne, C. L., & Nemeroff, C. B. (1999). 

Psychotropic drug interactions. In R. G. 

Robinson and W. R. Yates (Eds.), Psychiatric

treatment of the mentally ill (pp. 523-543). 

New York: Marcel Dekker, Inc.

Ernst, C. L., & Goldberg, J. F. (2002). The 

reproductive safety profile of mood stabilizers, 

atypical antipsychotics, and broad-spectrum 

psychotropics. Journal of Clinical Psychiatry, 

63(Suppl 4), 42-55.

Gold, L. H. (2000). Use of psychotropic 

medication during pregnancy: Risk management 

guidelines. Psychiatric Annals, 30, 421-432.
The Evidence 15 Selected Bibliography

Goldstein, D. J., & Corbin, L. A. (2000). 

Olanzapine-exposed pregnancies and 

lactation: Early experience. Journal of Clinical 

Psychopharmacology, 20, 399-403.

Ito, S. (2000). Drug therapy for breast-feeding 

women. New England Journal of Medicine, 343,

118-126; erratum, 343, 1348.

Koren, G., Cohen, T., Chitayat, D., Kapur, B., 

Remington, G., Reid, D. M., et al. (2002). Use of 

atypical antipsychotics during pregnancy and the 

risk of neural tube defects in infants. American

Journal of Psychiatry, 159, 136-137.

Lamotrigine Pregnancy Registry. A 

project conducted by Glaxo-SmithKline. 

http://pregnancyregistry.gsk.com/lamotrigine.html

Lane, H. Y., Jann, M. W., Chang, Y. C., Chiu, 

C. C., Huang, M. C., Lee, S. H., et al. (2001). 

Repeated ingestion of grapefruit juice does 

not alter clozapine’s steady-state plasma levels, 

effectiveness, and tolerability. Journal of Clinical 

Psychiatry, 62, 812-817.

Llewellyn, A., & Stowe, Z. N. (1998). Psychotropic 

medications in lactation. Journal of Clinical 

Psychiatry, 59(Suppl 2), 41-52.

Masand, P. S., & Gupta, S. (2003). Long-acting 

injectable antipsychotics in the elderly: 

Guidelines for effective use. Drugs & Aging, 

20, 1099-1110.

McCarthy, R. H. (1994). Seizures following 

smoking cessation in a clozapine responder. 

Pharmacopsychiatry, 27, 210-11.

McKenna, K., Koren, G., Tetelbaum, M., Wilton, L. 

Shakir, S., Diav-Citrin, O., et al. (2005). Pregnancy 

outcome of women using atypical antipsychotic 

drugs: A prospective comparative study. Journal 

of Clinical Psychiatry, 66, 444-449.

Mintzer, J., & Targum, S. D. (2003). Psychosis 

in elderly patients: Classification and 

pharmacotherapy. Journal of Geriatric 

Psychiatry and Neurology, 16, 199-206.

Mortola, J. F. (1989). The use of psychotropic 

agents in pregnancy and lactation. Psychiatric 

Clinics of North America, 12, 69-87.

Newport, D. J., Calamaras, M. R., D. V.ne, C. L., 

Donovan, J., Beach, A. J., Winn, S., et al. (2007). 

Atypical antipsychotic administration during 

late pregnancy: Placental passage and obstetrical 

outcomes. American Journal of Psychiatry, 164, 

1214-1220.

Nonacs, R., & Cohen, L. S. (1998). Postpartum 

mood disorders: Diagnosis and treatment 

guidelines. Journal of Clinical Psychiatry, 

59(Suppl 2), 34-40.

Nulman, I., Rovet, J., Stewart, D. E., Wolpin, 

J., Gardner, H. A., & Theis, J. G. W. (1997). 

Neurodevelopment of children exposed in utero 

to antidepressant drugs. New England Journal 

of Medicine, 336, 258-262.

Ordean, A., Midmer, D., Graves, L., Payne, 

S., Hunt, G., & the PRIMA Group. (2008). 

Pregnancy-Related Issues in the Management 

of Addictions (PRIMA). A reference for care 

providers. Ontario, Canada: University of 

Toronto, Department of Family and Community 

Medicine, Retrieved from 

http://www.addictionpregnancy.ca

Organization of Teratology Information Specialists. 

http://otispregnancy.org 

Patton, S. W., Misri, S., Corral, M. R., Perry, 

K. F., and Kuan, & A. F. (2002). Antipsychotic 

medication during pregnancy and lactation in 

women with schizophrenia: Evaluating the risk. 

Canadian Journal of Psychiatry, 47, 959-965.
Selected Bibliography 16 The Evidence

Drugs in Pregnancy and Breastfeeding.

[Web page]. http://www.perinatology.com/

exposures/druglist.htm 

Schou, M. (1990). Lithium treatment during 

pregnancy, delivery, and lactation: An update. 

Journal of Clinical Psychiatry, 51, 410-413.

Toren, P., Ratner, S., Laor, N., & Weizman, A. 

(2004). Benefit-risk assessment of atypical 

antipsychotics in the treatment of schizophrenia 

and comorbid disorders in children and 

adolescents. Drug Safety, 27, 1135-1156.

Toxicology Data Network: LactMed: Drugs 

and Lactation Database. Available from 

http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT

Trixler, M., Gáti, A., Fekete, S., & Tényi, T. (2005). 

Use of antipsychotics in the management of 

schizophrenia during pregnancy. Drugs, 65, 

1193-1206.

Viguera, A. C., Cohen, L. S., Baldessarini, R. J., & 

Nonacs, R. (2002). Managing bipolar disorder 

during pregnancy: Weighing the risks and 

benefits. Canadian Journal of Psychiatry, 47,

426-436.

Yaeger, D., Smith, H. G., & Altshuler, L. L. 

(2006). Atypical antipsychotics in the treatment 

of schizophrenia during pregnancy and the 

postpartum. American Journal of Psychiatry, 

163, 2064-2070.

Yogev, Y., Ben-Haroush, A., & Kaplan, B. (2002). 

Maternal clozapine treatment and decreased 

fetal heart rate variability. International Journal 

of Gynecology & Obstetrics, 79, 259-260.

Symptom assessment 

Bell, M., Fiszdon, J., Richardson, R. Lysaker, 

P., & Bryson, G. (2007). Are self-reports 

valid for schizophrenia patients with poor 

insight? Relationship of unawareness of illness 

to psychological self-report instruments. 

Psychiatry Research, 151, 37-46.

Niv, N., Cohen, A. N., Mintz, J., Ventura, J., & 

Young, A.S. (2007). The validity of using patient 

self-report to assess psychotic symptoms in 

schizophrenia. Schizophrenia Research, 90, 

245-250.

Rush, A. J., Jr., First, M. B., & Blacker, D. (Eds.). 

(2008). Handbook of psychiatric measures

(2nd ed.). Arlington, VA: American Psychiatric 

Publishing, Inc.

Sajatovic, M., & Ramirez, L. F. (2003). Rating 

scales in mental health (2nd ed.). Hudson, Ohio: 

Lexi-Comp, Inc. 
The Evidence 17 Selected Bibliography

Treatment-resistant 

schizophrenia

Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. 

(1988). Clozapine for the treatment-resistant 

schizophrenic: A double-blind comparison with 

chlorpromazine. Archives of General Psychiatry, 

45, 789-796.

Kelly, D. L., Conley, R. R., Richardson, C. M., 

Tamminga, C. A., & Carpenter, W. T. (2003). 

Adverse effects and laboratory parameters of 

high-dose olanzapine vs. clozapine in treatmentresistant schizophrenia. Annals of Clinical 

Psychiatry, 15, 181-186.

Lerner, V., Libov, I., Kotler, M., & Strous, 

R. D. (2004). Combination of “atypical” 

antipsychotic medication in the management 

of treatment-resistant schizophrenia and 

schizoaffective disorder. Progress in NeuroPsychopharmacology & Biological Psychiatry, 

28, 89-98.

McEvoy, J. P., Lieberman, J. A., Stroup, T. S., 

Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., 

et al. (2006). Effectiveness of clozapine versus 

olanzapine, quetiapine, and risperidone in 

patients with chronic schizophrenia who did 

not respond to prior atypical antipsychotic 

treatment. American Journal of Psychiatry, 

163, 600-610.

Rosenheck, R., Cramer, J., Xu, W., Thomas, J., 

Henderson, W., Frisman, L., et al. (1997). 

A comparison of clozapine and haloperidol 

in hospitalized patients with refractory 

schizophrenia. Department of Veterans 

Affairs Cooperative Study Group on Clozapine 

in Refractory Schizophrenia. New England 

Journal of Medicine, 337, 809-815.

The Evidence 19 References

The Evidence

References 

The following list includes the references for all citations in the KIT.

Arranz, M. J., & de Leon, J. 

(2007). Pharmacogenetics and 

pharmacogenomics of schizophrenia: 

A review of last decade of research. 

Molecular Psychiatry, 12, 707-747.

Bauer, M. S. (2002). A review of 

quantitative studies of adherence 

to mental health clinical practice 

guidelines. Harvard Review of 

Psychiatry, 10, 138-153.

Becker, D. R., Bond, G. R., McCarthy, 

D., Thompson, D., Xie, H., McHugo, 

G. J., et al. (2001). Converting day 

treatment centers to supported 

employment programs in Rhode Island. 

Psychiatric Services, 52, 351-357.

Bond, G. R., & Salyers, M. P. (2004). 

Prediction of outcome from the 

Dartmouth Assertive Community 

Treatment Fidelity Scale. CNS 

Spectrums, 9, 937-942.

Cabana, M. D., Rand, C. S., Powe, 

N. R., Wu, A. W., Wilson, M. H., 

Abboud, P. A. C., et al. (1999). 

Why don’t physicians follow clinical 

practice guidelines? A framework for 

improvement. Journal of the American 

Medical Association, 282, 1458-1465.

Carbamazepine package insert. See 

http://www.pharma.us.novartis.com/

product/pi/pdf/tegretol.pdf
References 20 The Evidence

Cradock, J., Young, A. S., & Sullivan, G. (2001). 

The accuracy of medical record documentation 

in schizophrenia. Journal of Behavioral Health 

Services & Research, 28, 456-465.

Drake, R. E., Bond, G. R., & Rapp, C. A. (2006). 

Explaining the variance within supported 

employment programs: Comment on “what 

predicts supported employment outcomes?” 

Community Mental Health Journal, 42, 315-318.

Frackiewicz, E. J., Herrera, J. M., Sramek, 

J. J., Collazo, I. Y., & Lawson, W. B. (2002). 

Risperidone in the treatment of Hispanic 

inpatients with schizophrenia: A pilot study. 

Psychiatry 65(4): 371-374.

Ferris, F. D., & Librach, S. L. (2005). Models, 

standards, guidelines. Clinics in Geriatric 

Medicine, 21, 17-44.

Ganju, V. (2004, June). Evidence-based practices: 

Responding to the challenge. Presented at 

the NAS. H.D Commissioner’s Meeting, San 

Francisco, CA.

Howard, P. B., El-Mallakh, P., Miller, A. L., 

Rayens, M. K., Bond, G. R., Henderson, K., 

et al. (2009). Prescriber fidelity to a medication 

management evidence-based practice in the 

treatment of schizophrenia. Psychiatric Services, 

60, 929-935.

Hyde, P. S., Falls, K., Morris, J. A., & Schoenwald, 

S. K. (2003). Turning knowledge into practice: 

A manual for behavioral health administrators 

and practitioners about understanding and 

implementing evidence-based practices. Boston: 

Technical Assistance Collaborative. Available 

from http://www.tacinc.org 

Institute of Medicine. (2006). Improving the quality 

of health care for mental and substance-use 

conditions: Quality Chasm Series. Washington, 

DC: National Academy of Sciences.

Katon, W., Von Korff, M., Lin, E., Walker, 

E., Simon, G. E., Bush, T., et al. (1995). 

Collaborative management to achieve treatment 

guidelines: Impact on depression in primary 

care. Journal of the American Medical 

Association, 273, 1026-1031.

Lehman, A. F., & Steinwachs, D. M. (1998). 

Patterns of usual care for schizophrenia: 

Initial results from the Schizophrenia Patient 

Outcomes Research Team (PORT) Client 

Survey. Schizophrenia Bulletin, 24, 11-20.

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., 

Swartz, M. S., Rosenheck, R., Perkins, D. O., 

et al. (2005). Effectiveness of antipsychotic drugs 

in patients with chronic schizophrenia. New 

England Journal of Medicine, 353, 1209-1223.

Lin, K. M., & Finder, E. (1983). Neuroleptic 

dosage for Asians. American Journal of 

Psychiatry, 140, 490-491.

Lindenmayer, J. P., Volavka, J., Lieberman, J., 

Sheitman, B., Citrome, L., Chakos, M., et al. 

(2001). Olanzapine for schizophrenia refractory 

to typical and atypical antipsychotics: An openlabel, prospective trial. Journal of Clinical 

Psychopharmacology, 21, 448-453.

Marder, S. R., Essock, S. M., Miller, A. L., 

Buchanan, R. W., Davis, J. M., Kane, J. M., 

et al. (2002). The Mount Sinai Conference 

on the pharmacotherapy of schizophrenia. 

Schizophrenia Bulletin, 28, 5-16.

Marder, S. R., Essock, S. M., Miller, A. L., 

Buchanan, R. W., Casey, D. E., Davis, J. M., 

et al. (2004). Physical health monitoring of 

patients with schizophrenia. American Journal of 

Psychiatry, 161, 1334-1349.
Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, 

K., Chen, Y., Ertugrul, A., et al. (2008). 

A randomized, double-blind comparison 

of clozapine and high-dose olanzapine in 

treatment-resistant patients with schizophrenia. 

Journal of Clinical Psychiatry, 69, 274-285.

Monash Institute of Health Services Research 

(2006). Evidence-Based Answers to Clinical 

Questions for Busy Clinicians. The Centre for 

Clinical Effectiveness, Melbourne, Australia.

National Advisory Mental Health Council 

Workgroup on Child and Adolescent Mental 

Health Intervention Development and 

Deployment. (2001). Blueprint for change: 

Research on child and adolescent mental health.

Rockville, MD: National Institute of Mental 

Health. Available from http://www.nimh.nih.gov

New Freedom Commission on Mental Health. 

(2003). Achieving the promise: Transforming 

mental health care in America. Final Report. 

(DHHS Publication. No. SMA-03-3832). 

Rockville, MD: Author.

Ng, C. H., Chong, S., Lambert, T., Fan, A., 

Hackett, L., Mahendran, R., et al., (2005). 

An inter-ethnic comparison study of clozapine 

dosage, clinical response and plasma levels. 

International Clinical Psychopharmacology. 

20(3) 163-168.

Parks, J. J. (2007). Implementing practice 

guidelines: Lessons from public mental health 

settings. Journal of Clinical Psychiatry, 68(Suppl 

4), 45-48.

Peters, T. J., & Waterman, R. H. (1982). In search 

of excellence. New York: Harper & Row.

Rush, A. J., Jr., First, M. B., & Blacker, D. (Eds.). 

(2008). Handbook of Psychiatric Measures

(2nd ed.). Arlington, VA: American Psychiatric 

Publishing, Inc.

Sackett, D. L., Rosenberg, W. M. C., Gray, 

J. A. M., Haynes, A. B., & Richardson, W. S. 

(1996). Evidence based medicine: What it is and 

what it isn’t. British Medical Journal, 312, 71-72.

Sajatovic, M., & Ramirez, L. F. (2003). Rating 

Scales in Mental Health (2nd ed.). Hudson, 

Ohio: Lexi-Comp, Inc. 

Sernyak, M. J., Dausey, D., Desai, R., 

& Rosenheck, R. (2003). Prescribers’ 

nonadherence to treatment guidelines for 

schizophrenia when prescribing neuroleptics. 

Psychiatric Services, 54, 246-248.

Simon, G. E., VonKorff, M., Rutter, C., & Wagner, 

E. (2000). Randomised trial of monitoring, 

feedback, and management of care by telephone 

to improved treatment of depression in primary 

care. British Medical Journal, 320, 550-554.

Stahl, S. M., & Grady, M. M. (2004). A critical 

review of atypical antipsychotic utilization: 

Comparing monotherapy with polypharmacy 

and augmentation. Current Medicinal 

Chemistry, 11, 313-327.

Taylor, A. C., Bond, G. R., Tsai, J., Howard, P. B., 

El-Mallakh, P., Finnerty, M., et al. (2009). Scales 

to evaluate quality of medication management: 

Development and psychometric properties. 

Administration and Policy in Mental Health 

and Mental Health Services Research. Published 

online February 27, 2009. DOI 10.1007/s10488-

009-0209-z

Teague, G. R., Drake, R. E., & Ackerson, T. 

(1995). Evaluating use of continuous treatment 

teams for persons with mental illness and 

substance abuse. Psychiatric Services, 46,

689-695.

The Evidence 21 References
References 22 The Evidence

Toprac, M. G., Dennehy, E. B., Carmody, T. J., 

Crismon, M. L., Miller, A. L., Trivedi, M., et al. 

(2006). Implementation of the Texas Medication 

Algorithm Project patient and family education 

program. Journal of Clinical Psychiatry, 67, 

1362-1372.

U.S. Department of Health and Human Services. 

(1999). Mental health: A report of the Surgeon 

General. Rockville, MD: U.S. Department of 

Health and Human Services, Substance Abuse 

and Mental Health Services Administration, 

Center for Mental Health Services, and National 

Institutes of Health, National Institute of 

Mental Health.

U.S. Department of Health and Human Services. 

(2001). Mental health: Culture, race, and 

ethnicity—A supplement to Mental health: 

A report of the Surgeon General. Rockville, 

MD: U.S. Department of Health and Human 

Services, Substance Abuse and Mental Health 

Services Administration, Center for Mental 

Health Services.

Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, 

J. P., Citrome, L., McEvoy, J. P., et al. (2002). 

Clozapine, olanzapine, risperidone, and 

haloperidol in the treatment of patients with 

chronic schizophrenia and schizoaffective 

disorder. American Journal of Psychiatry, 159, 

255–262; erratum, 159, 2132.

Weiden, P. J. (2007). Discontinuing and switching 

antipsychotic medications: Understanding the 

CATIE schizophrenia trial. Journal of Clinical 

Psychiatry, 68(Suppl 1), 12-19.

Weinmann, S., Koesters, M., & Becker, T. (2007). 

Effects of implementation of psychiatric 

guidelines on provider performance and patient 

outcome: Systematic review. Acta Psychiatrica 

Scandinavica, 115, 420-433.

Wells, K. B., Sherbourne, C., Schoenbaum, 

M., Duan, N., Meredith, L., Unutzer, J., et 

al. (2000). Impact of disseminating quality 

improvement programs for depression in 

managed primary care: A randomized controlled 

trial. Journal of the American Medical 

Association, 283, 212-220.

Worrall, G., Angel, J., Chaulk, P., Clarke, C., 

& Robbins, M. (1999). Effectiveness of 

an educational strategy to improve family 

physicians’ detection and management of 

depression: A randomized controlled trial. 

Canadian Medical Association Journal, 

161, 37-40.

Young, A. S., Sullivan, G., Burnam, M. A., & 

Brook, R. H. (1998). Measuring the quality of 

outpatient treatment for schizophrenia. Archives 

of General Psychiatry, 55, 611-617.

Young, G. J., Mohr, D. C., Meterko, M., Seibert, 

M. N., & McGlynn, G. (2006). Psychiatrists’ 

self-reported adherence to evidence-based 

prescribing practices in the treatment of 

schizophrenia. Psychiatric Services, 57, 130-132.
The Evidence 23 Acknowledgments

The Evidence

Acknowledgments

The materials included in the MedTEAM KIT were developed through the 

University of Texas at San Antonio. In partnership with many other collaborators, 

including clinicians, researchers, consumers, family members, and administrators, 

and operating under the direction of the Substance Abuse and Mental Health 

Services Administration, Center for Mental Health Services, these materials were 

evaluated and revised. 

We wish to acknowledge the many people who contributed to all aspects of this 

project. In particular, we wish to acknowledge the contributors and consultants 

on the next few pages.
Acknowledgments 24 The Evidence

SAMHSA Center for Mental Health Services, Oversight Committee

Michael English (deceased)

Division of Service and Systems Improvement

Rockville, Maryland

Neal B. Brown

Community Support Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland

Sandra Black

Community Support Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland

Crystal R. Blyler

Community Support Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland 

Pamela Fischer

Homeless Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland

Sushmita Shoma Ghose

Community Support Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland 

Patricia Gratton

Division of Service and Systems Improvement

Rockville, Maryland

Betsy McDonel Herr 

Community Support Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland

Larry D. Rickards

Homeless Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland

Ken Thompson

SAMHSA Center for Mental Health Services

Rockville, Maryland 

Co-leaders

Tom Mellman

Dartmouth Medical School

Hanover, New Hampshire

Alexander Miller

University of Texas Health Science Center 

at San Antonio

San Antonio, Texas 

Troy Moore

University of Texas at San Antonio

San Antonio, Texas
The Evidence 25 Acknowledgments

Contributors 

Neal Adams

California Institute of Mental Health

Soquel, California 

Charity Appell

Ascutney, Vermont

Robert Arizpe

San Antonio State Hospital

San Antonio, Texas

Kate Bell

Humboldt County Department of Mental Health

Humboldt, California

Crystal R. Blyler

Community Support Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland 

Gary Bond

Indiana University, Purdue University 

at Indianapolis

Indianapolis, Indiana

Neal Brown

Community Support Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland

Barbara Burns

Duke University School of Medicine

Durham, North Carolina

Michael J. Cohen

National Alliance on Mental Illness (NAMI)

Concord, New Hampshire

Catherine Craig

University of Texas Health Science Center 

at San Antonio

San Antonio, Texas

Lynn Crismon

University of Texas College of Pharmacy

San Antonio, Texas

Albana Dassori

University of Texas Health Science Center 

at San Antonio

San Antonio, Texas

Robert Drake

Dartmouth Psychiatric Research Center

Concord, New Hampshire

Paul Eisenhauer

San Antonio, Texas

Susan Essock

The Mount Sinai School of Medicine

New York, New York

Anita Everett

SAMHSA

Rockville, Maryland

Molly Finnerty

New York State Office of Mental Health

New York, New York

Vijay Ganju

National Association of State Mental Health 

Program Directors Research Institute

Alexandria, Virginia
Acknowledgments 26 The Evidence

Sushmita Shoma Ghose

Community Support Programs Branch

Division of Service and Systems Improvement

Rockville, Maryland 

Cindy Hopkins

Texas Department of Mental Health and Mental 

Retardation

San Antonio, Texas

Howard H. Goldman

University of Maryland School of Medicine

Baltimore, Maryland

Paul G. Gorman

Dartmouth Psychiatric Research Center

Lebanon, New Hampshire

Pat Howard

University of Kentucky

Lexington, Kentucky

Karin Kalk

California Institute of Mental Health

Ladera Ranch, California

H. Stephen Leff

The Evaluation Center at the Human Services 

Research Institute

Cambridge, Massachusetts

Natalie Maples

University of Texas at San Antonio

San Antonio, Texas

Steven Marder

University of California at Los Angeles

Los Angeles, CA

Noel Mazade

National Association of State Mental Health 

Program Directors Research Institute

Alexandria, Virginia

Carolee Moore

Center for Health Care Services

San Antonio, Texas

Mona Neaderhiser

University of Texas Health Science Center 

at San Antonio

San Antonio, Texas

Joseph Parks

Missouri Department of Mental Health

Jefferson City, Missouri 

Frank Perez

San Antonio, Texas

Ernest Quimby

Howard University

Washington, D.C.

Steven Shon

Texas Department of Mental Health and 

Mental Retardation

Austin, Texas

Gus Sicard

Center for Healthcare Services

San Antonio, Texas

Steven Steury

Department of Mental Health

Washington, D.C.

Patricia Suppes

Stanford University School of Medicine

Stanford, Connecticut

Ken Thompson

SAMHSA Center for Mental Health Services

Rockville, Maryland
The Evidence 27 Acknowledgments

Marcia Toprac

Texas Department of Mental Health 

and Mental Retardation

San Antonio, Texas

William Torrey

Dartmouth Medical School

Hanover, New Hampshire

Laura Van Tosh

Olympia, Washington

Madhukar Trivedi

University of Texas at San Antonio

San Antonio, Texas

Dawn Velligan

University of Texas at San Antonio

San Antonio, Texas

Ellen Weissman

The Mount Sinai School of Medicine

New York, New York

Consultants to the National Implementing Evidence-Based Practices Project

Dan Adams

St. Johnsbury, Vermont 

Diane C. Alden

New York State Office of Mental Health 

New York, New York

Lindy Fox Amadio 

Dartmouth Psychiatric Research Center

Concord, New Hampshire

Diane Asher

The University of Kansas

Lawrence, Kansas

Stephen R. Baker

University of Maryland School of Medicine

Baltimore, Maryland

Stephen T. Baron 

Department of Mental Health

Washington, D.C.

Deborah R. Becker 

Dartmouth Psychiatric Research Center

Lebanon, New Hampshire

Nancy L. Bolton

Cambridge, Massachusetts

Patrick E. Boyle

Case Western Reserve University

Cleveland, Ohio

Mike Brady

Adult and Child Mental Health Center

Indianapolis, Indiana

Ken Braiterman

National Alliance on Mental Illness (NAMI)

Concord, New Hampshire 

Janice Braithwaite

Snow Hill, Maryland

Michael Brody 

Southwest Connecticut Mental Health Center

Bridgeport, Connecticut

Mary Brunette 

Dartmouth Psychiatric Research Center

Concord, New Hampshire
Acknowledgments 28 The Evidence

Sharon Bryson

Ashland, Oregon

Barbara J. Burns 

Duke University School of Medicine 

Durham, North Carolina

Jennifer Callaghan

The University of Kansas

School of Social Welfare

Lawrence, Kansas

Kikuko Campbell

Indiana University–Purdue University 

Indianapolis, Indiana

Linda Carlson 

University of Kansas

Lawrence, Kansas 

Diana Chambers

Department of Health Services 

Burlington, Vermont

Alice Claggett

University of Toledo College of Medicine

Toledo, Ohio

Marilyn Cloud

Department of Health and Human Services

Concord, New Hampshire

Melinda Coffman 

The University of Kansas

Lawrence, Kansas 

Jon Collins

Office of Mental Health and Addiction Services

Salem, Oregon

Laurie Coots

Dartmouth Psychiatric Research Center

Lebanon, New Hampshire

Judy Cox

New York State Office of Mental Health

New York, New York 

Harry Cunningham

Dartmouth Psychiatric Research Center

Concord, New Hampshire

Gene Deegan

University of Kansas

Lawrence, Kansas

Natalie D. L.ca

Indiana University–Purdue University 

Indianapolis, Indiana

Robert E. Drake 

Dartmouth Psychiatric Research Center

Lebanon, New Hampshire

Molly Finnerty

New York State Office of Mental Health

New York, New York 

Laura Flint

Dartmouth Evidence Based Practices Center

Burlington, Vermont

Vijay Ganju 

National Association of State Mental Health 

Program Directors Research Institute

Alexandria, Virginia

Susan Gingerich

Narberth, Pennsylvania

Phillip Glasgow

Wichita, Kansas

Howard H. Goldman

University of Maryland School of Medicine

Baltimore, Maryland
The Evidence 29 Acknowledgments

Paul G. Gorman

Dartmouth Psychiatric Research Center

Lebanon, New Hampshire

Gretchen Grappone

Concord, New Hampshire

Eileen B. Hansen

University of Maryland School of Medicine 

University of Maryland, Baltimore 

Kathy Hardy 

Strafford, Vermont 

Joyce Hedstrom 

Courtland, Kansas 

Lon Herman 

Department of Mental Health

Columbus, Ohio 

Lia Hicks

Adult and Child Mental Health Center

Indianapolis, Indiana

Debra Hrouda

Case Western Reserve University

Cleveland, Ohio

Bruce Jensen

Indiana University–Purdue University 

Indianapolis, Indiana

Clark Johnson 

Salem, New Hampshire 

Amanda M. Jones

Indiana University–Purdue University 

Indianapolis, Indiana

Joyce Jorgensen

Department of Health and Human Services

Concord, New Hampshire

Hea-Won Kim

Indiana University–Purdue University 

Indianapolis, Indiana

David A. Kime

Transcendent Visions and Crazed Nation Zines

Fairless Hills, Pennsylvania 

Dale Klatzker 

The Providence Center

Providence, Rhode Island 

Kristine Knoll

Dartmouth Psychiatric Research Center

Lebanon, New Hampshire

Bill Krenek

Department of Mental Health 

Columbus, Ohio

Rick Kruszynski

Case Western Reserve University

Cleveland, Ohio

H. Stephen Leff 

The Evaluation Center at the Human Services 

Research Institute

Cambridge, Massachusetts

Treva E. Lichti

National Alliance on Mental Illness (NAMI) 

Wichita, Kansas 

Wilma J. Lutz

Ohio Department of Mental Health

Columbus, Ohio 

Anthony D. Mancini

New York State Office of Mental Health 

New York, New York

Paul Margolies

Hudson River Psychiatric Center

Poughkeepsie, New York 
Acknowledgments 30 The Evidence

Tina Marshall

University of Maryland School of Medicine

Baltimore, Maryland

Ann McBride (deceased)

Oklahoma City, Oklahoma

William R. McFarlane

Maine Medical Center

Portland, Maine

Mike McKasson

Adult and Child Mental Health Center

Indianapolis, Indiana 

Alan C. McNabb

Ascutney, Vermont 

Meka McNeal 

University of Maryland School of Medicine

Baltimore, Maryland

Ken Minkoff

ZiaLogic

Albuquerque, New Mexico

Michael W. Moore 

Office of Mental Health and Addiction Services

Salem, Oregon

Roger Morin 

The Center for Health Care Services

San Antonio, Texas 

Lorna Moser

Indiana University–Purdue University 

Indianapolis, Indiana

Kim T. Mueser

Dartmouth Psychiatric Research Center

Concord, New Hampshire

Britt J. Myrhol

New York State Office of Mental Health 

New York, New York

Bill Naughton 

Southeastern Mental Health Authority

Norwich, Connecticut 

Nick Nichols

Department of Health 

Burlington, Vermont

Bernard F. Norman

Northeast Kingdom Human Services

Newport, Vermont

Linda O’Malia

Oregon Health and Science University

Portland, Oregon

Ruth O. Ralph

University of Southern Maine

Portland, Maine 

Angela L. Rollins

Indian University–Purdue University 

Indianapolis, Indiana

Tony Salerno

New York State Office of Mental Health 

New York, New York

Diana C. Seybolt

University of Maryland School of Medicine

Baltimore, Maryland

Patricia W. Singer 

Santa Fe, New Mexico

Mary Kay Smith

University of Toledo

Toledo, Ohio 
The Evidence 31 Acknowledgments

Diane Sterenbuch

Bethesda, Maryland 

Bette Stewart

University of Maryland School of Medicine

Baltimore, Maryland

Steve Stone

Mental Health and Recovery Board 

Ashland, Ohio

Maureen Sullivan

Department of Health and Human Services

Concord, New Hampshire

Beth Tanzman

Vermont Department of Health

Burlington, Vermont

Greg Teague

University of Southern Florida

Tampa, Florida

Boyd J. Tracy

Dartmouth Psychiatric Research Center

Lebanon, New Hampshire 

Laura Van Tosh 

Olympia, Washington 

Joseph A. Vero

National Alliance on Mental Illness (NAMI) 

Aurora, Ohio

Barbara L. Wieder

Case Western Reserve University

Cleveland, Ohio

Mary Woods

Westbridge Community Services

Manchester, New Hampshire
Acknowledgments 32 The Evidence

Special thanks

Special thanks to the Robert Wood Johnson Foundation for its generous contribution. 

Production, editorial, and graphics support

Carolyn Boccella Bagin

Center for Clear Communication, Inc.

Rockville, Maryland

Jason Davis

Westat

Rockville, Maryland 

Sushmita Shoma Ghose 

Westat

Rockville, Maryland 

Julien P. Hofberg

Westat

Rockville, Maryland 

Chandria Jones

Westat

Rockville, Maryland

Glynis Jones

Westat

Rockville, Maryland 

Tina Marshall 

Westat

Rockville, Maryland 

Mary Anne Myers

Westat

Rockville, Maryland 

28610.0510.8712010401

HHS Publication No. SMA-10-4548

Printed 2010